Global Leading Market Research Publisher QYResearch announces the release of its latest report “SEPT7 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global SEPT7 Antibody market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for SEPT7 Antibody was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
For cell biologists, cancer metastasis researchers, and cytoskeleton specialists, four persistent experimental pain points dominate SEPT7-related workflows: validating SEPT7 (Septin 7, also known as CDC10, Septin-7, or hCDC10) expression as a core component of the septin filament network, distinguishing monoclonal vs. polyclonal antibody performance across applications (western blot, IHC, IF, IP), detecting SEPT7 within hetero-oligomeric septin complexes (SEPT2-SEPT6-SEPT7, SEPT7-SEPT9 dimers) without cross-reactivity to other septin family members (13 known human septins), and maintaining lot-to-lot consistency for longitudinal metastasis studies. SEPT7 is a unique septin required for filament formation. It has also been reported to be involved in migration and invasion in various cancer cells. Growing patient base, launch of SEPT7 antibody-based therapeutics, increasing penetration of antibody drugs, and continuous regulation across the biopharmaceutical industry are the key factors driving the increase in SEPT7 antibody market revenue. This report delivers a data-driven roadmap for cytoskeleton researchers, cancer biology investigators, and drug discovery scientists.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984530/sept7-antibody
1. Market Drivers and Research Demand (2025–2026 Update)
SEPT7 is a core septin essential for septin filament assembly, forming hexameric (SEPT2-SEPT6-SEPT7) and octameric (SEPT2-SEPT6-SEPT7-SEPT3) complexes. It localizes to the cytoskeleton, cell cortex, and midbody during cytokinesis. SEPT7 dysregulation is implicated in cancer (glioblastoma, breast, colorectal, ovarian, prostate), neurodegeneration (Alzheimer’s, Parkinson’s), and developmental disorders. Demand drivers include:
- Cancer metastasis research: SEPT7 downregulation correlates with increased migration, invasion, and poor prognosis; antibody used for IHC in tumor TMAs and IF in cell lines
- Septin filament dynamics: SEPT7 is required for higher-order filament assembly; antibody used for immunofluorescence and co-IP with other septins
- Cytokinesis and cell division studies: SEPT7 localizes to the midbody; antibody used in mitosis research
- Neurodegenerative disease: Septin aggregates reported in Alzheimer’s and Huntington’s; antibody used for brain tissue IHC
Based on supplier catalog data (Abcam, Thermo Fisher, Proteintech, Merck, Novus), SEPT7 antibody unit sales grew 7–9% YoY (2024–2025), driven by increased cancer metastasis research and expanding septin biology studies in China and Europe (>50 SEPT7-related publications in 2025).
2. Monoclonal vs. Polyclonal SEPT7 Antibodies
| Parameter | Monoclonal SEPT7 Antibody | Polyclonal SEPT7 Antibody |
|---|---|---|
| Specificity | Very high (single epitope) | High (multiple epitopes) |
| Batch consistency | Excellent (identical) | Variable |
| IF performance | Excellent (clean filament staining) | Good (affinity-purified) |
| WB performance | Clean single band (~55 kDa) | Single band if affinity-purified |
| IP performance | Variable (epitope masking in complexes) | Good (multiple epitopes) |
| Cross-reactivity to other septins | Low (if well-designed) | Moderate (conserved GTPase domain) |
| Market share | ~50% | ~50% |
Critical note – SEPT7 as core septin: SEPT7 forms complexes with SEPT2 and SEPT6 (hexamer) or SEPT3 (octamer). For IF, monoclonal antibodies provide cleaner filament staining. For co-IP of septin complexes, polyclonal antibodies perform better due to multiple epitope availability.
3. Application Performance Requirements
| Application | Share | Key Requirements | Preferred Type | Dilution |
|---|---|---|---|---|
| Immunofluorescence (IF) | ~35% | Cytoskeletal filament staining; colocalization with actin/tubulin | Monoclonal | 1:50–1:500 |
| Western Blot (WB) | ~30% | Single band ~55 kDa; positive control: HeLa, HEK293, mouse brain lysates | Both | 1:500–1:2,000 |
| Immunohistochemistry (IHC) | ~15% | FFPE tissue; cytoplasmic/membrane staining in cancer tissues | Monoclonal or affinity-purified | 1:50–1:500 |
| Immunoprecipitation (IP) | ~12% | Native SEPT7; pull-down of septin complexes (SEPT2, SEPT6, SEPT9) | Polyclonal | 2–10 μg/IP |
| ELISA | ~5% | Lysate quantitation | Monoclonal | 1:500–1:5,000 |
| Others | ~3% | Flow cytometry, tissue arrays | Monoclonal | 1:50–1:200 |
Typical case – SEPT7 in glioblastoma migration (US, 2025):
A Boston cancer center studied SEPT7 expression in glioblastoma (GBM) patient samples (n=85) and cell lines (U87, U251). Using monoclonal mouse anti-SEPT7 antibody (clone 5F9), IF (1:100) showed SEPT7 localized to the leading edge of migrating GBM cells. WB (1:1,000) confirmed SEPT7 downregulation in mesenchymal GBM subtype (45% of control, p<0.001) correlating with increased migration (transwell assay, r=-0.72). Patients with low SEPT7 IHC (H-score<100, n=28) had reduced overall survival (HR=2.34, p=0.008). The monoclonal antibody enabled consistent IHC scoring across 2 pathologists (ICC=0.92).
Typical case – Septin complex immunoprecipitation (China, 2025):
A Beijing research group used rabbit polyclonal SEPT7 antibody (5 μg/IP, raised against full-length recombinant SEPT7) to pull down septin complexes from HeLa cell lysates. IP-WB confirmed co-precipitation of SEPT2 (41 kDa), SEPT6 (50 kDa), and SEPT9 (65 kDa). The polyclonal antibody recognized both free SEPT7 and complex-bound SEPT7, enabling stoichiometric analysis of hexamer vs. octamer complex formation under different conditions (serum starvation, EGF stimulation).
4. Technical Bottlenecks and Quality Considerations
SEPT7 cross-reactivity with other septins: Human septin family includes 13 members with conserved GTPase domains (30-60% identity). Cross-reactivity risk:
| Septin | MW | Identity to SEPT7 | Cross-Reactivity Risk |
|---|---|---|---|
| SEPT2 | 41 kDa | ~40% | Moderate (different MW) |
| SEPT6 | 50 kDa | ~38% | Moderate |
| SEPT8 | 55 kDa | ~42% | Moderate (similar MW) |
| SEPT9 | 65 kDa | ~35% | Low (MW distinct) |
| SEPT11 | 50 kDa | ~36% | Moderate |
Validation: Use SEPT7 KO cells (available from Abcam, Thermo Fisher) to confirm antibody specificity. For IF, SEPT7 knockdown should significantly reduce filament staining.
SEPT7 fixation sensitivity for IF:
| Fixative | SEPT7 Preservation | Recommended |
|---|---|---|
| Methanol (-20°C, 5-10 min) | Excellent | Yes (preferred) |
| PFA (4%, 15 min) + permeabilization | Good | Yes (with 0.1% Triton X-100) |
| PFA > 30 min | Poor (epitope masking) | No |
| Acetone | Variable | Not recommended |
Exclusive forward view – SEPT7 as therapeutic target in cancer:
SEPT7 functions as a tumor suppressor in multiple cancers. Therapeutic strategies under investigation (2025-2026):
- Gene therapy: SEPT7 overexpression in glioblastoma (Phase I, China, 2024-2026)
- Small molecule stabilizers: Compounds preventing septin filament disassembly
- Biomarker applications: SEPT7 IHC as prognostic marker in breast, colorectal, and lung cancer
SEPT7 antibody applications in drug development: IHC for patient stratification, WB for target engagement in xenografts, IF for septin filament integrity assessment.
5. Regional Market Dynamics
| Region | Share | Key Drivers |
|---|---|---|
| North America | ~42% | Cancer metastasis research (NCI); cytoskeleton biology; glioblastoma research |
| Europe | ~30% | Septin biology (Germany, UK); cancer cell migration studies; neurodegenerative disease research |
| Asia-Pacific | ~22% | China (cancer metastasis, septin biology, >50 SEPT7 publications 2025); Japan (cytoskeleton, cell division); South Korea |
| Rest of World | ~6% | Australia; Brazil |
6. Competitive Landscape
Leading players covered in this report (full list): Merck, Bethyl Laboratories, GeneTex, RayBiotech, BosterBio, LifeSpan BioSciences, ProSci, Abnova Corporation, CUSABIO Technology, Abcam, Affinity Biosciences, ABclonal Technology, St John’s Laboratory, United States Biological, Thermo Fisher Scientific, Creative Biolabs, AAT Bioquest, Proteintech Group, Novus Biologicals, G Biosciences, Biobyt, Jingjie PTM BioLab, Wuhan Fine Biotech, Beijing Solarbio.
Tier 1 suppliers: Abcam, Thermo Fisher, Merck, Proteintech, Novus — multiple clones (monoclonal + polyclonal), KO validation for select products, extensive application data (IF, WB, IHC, IP).
Septin filament specialists: Abcam (ab131370, rabbit monoclonal, excellent IF staining); Thermo Fisher (PA5-103553, rabbit polyclonal); Proteintech (17437-1-AP, rabbit polyclonal, highly cited).
Price/performance: BosterBio, Bioss, GeneTex — adequate for routine WB, lower cost.
7. Market Segmentation Summary
Segment by Type: Monoclonal, Polyclonal
Segment by Application: Immunochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blot (WB), ELISA, Others
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
